Conditioned pain modulation in drug-naïve patients with de novo Parkinson's disease

Standard

Conditioned pain modulation in drug-naïve patients with de novo Parkinson's disease. / Grashorn, Wiebke; Fründt, Odette; Buhmann, Carsten; Wrobel, Nathalie; Schmidt, Katharina; Bingel, Ulrike.

In: Neurol Res Pract, Vol. 1, 2019, p. 27.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{0ce418461f4e4f29b966b3f69444082e,
title = "Conditioned pain modulation in drug-na{\"i}ve patients with de novo Parkinson's disease",
abstract = "Background: Pain is highly prevalent in patients with Parkinson's disease (PD), but underlying pathophysiological mechanisms are largely unclear. In many chronic pain syndromes deficits in endogenous pain inhibition have been detected that can be assessed using conditioned pain modulation paradigms. Previous studies employing this approach in medicated PD patients did not find abnormal pain inhibition. However, these results might have been confounded by residual dopaminergic medication.Methods: An established conditioned pain modulation paradigm was used in 17 drug-na{\"i}ve de novo PD patients and 17 healthy age and gender-matched controls. We tested i) whether conditioned pain modulation responses differed between the patient and control group and ii) whether pain inhibition differed between PD subtypes.Results: PD patients and healthy controls did not differ in their conditioned pain modulation responses. Furthermore, there were no significant differences in CPM responses depending on the PD subtype. However, at a descriptive level, tremor-dominant patients showed a tendency for better descending pain inhibition compared to akinetic-rigid and mixed type patients.Conclusions: In this first study investigating conditioned pain modulation in de novo PD patients, we found no additional impairment in descending pain modulation besides the known age-related decline. Our findings indicate that mechanisms other than an impaired descending inhibition contribute to high pain prevalence rates in PD and suggest that mechanisms underlying pain may differ between PD subtypes.",
author = "Wiebke Grashorn and Odette Fr{\"u}ndt and Carsten Buhmann and Nathalie Wrobel and Katharina Schmidt and Ulrike Bingel",
note = "{\textcopyright} The Author(s) 2019.",
year = "2019",
doi = "10.1186/s42466-019-0029-x",
language = "English",
volume = "1",
pages = "27",
journal = "Neurol Res Pract",
issn = "2524-3489",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Conditioned pain modulation in drug-naïve patients with de novo Parkinson's disease

AU - Grashorn, Wiebke

AU - Fründt, Odette

AU - Buhmann, Carsten

AU - Wrobel, Nathalie

AU - Schmidt, Katharina

AU - Bingel, Ulrike

N1 - © The Author(s) 2019.

PY - 2019

Y1 - 2019

N2 - Background: Pain is highly prevalent in patients with Parkinson's disease (PD), but underlying pathophysiological mechanisms are largely unclear. In many chronic pain syndromes deficits in endogenous pain inhibition have been detected that can be assessed using conditioned pain modulation paradigms. Previous studies employing this approach in medicated PD patients did not find abnormal pain inhibition. However, these results might have been confounded by residual dopaminergic medication.Methods: An established conditioned pain modulation paradigm was used in 17 drug-naïve de novo PD patients and 17 healthy age and gender-matched controls. We tested i) whether conditioned pain modulation responses differed between the patient and control group and ii) whether pain inhibition differed between PD subtypes.Results: PD patients and healthy controls did not differ in their conditioned pain modulation responses. Furthermore, there were no significant differences in CPM responses depending on the PD subtype. However, at a descriptive level, tremor-dominant patients showed a tendency for better descending pain inhibition compared to akinetic-rigid and mixed type patients.Conclusions: In this first study investigating conditioned pain modulation in de novo PD patients, we found no additional impairment in descending pain modulation besides the known age-related decline. Our findings indicate that mechanisms other than an impaired descending inhibition contribute to high pain prevalence rates in PD and suggest that mechanisms underlying pain may differ between PD subtypes.

AB - Background: Pain is highly prevalent in patients with Parkinson's disease (PD), but underlying pathophysiological mechanisms are largely unclear. In many chronic pain syndromes deficits in endogenous pain inhibition have been detected that can be assessed using conditioned pain modulation paradigms. Previous studies employing this approach in medicated PD patients did not find abnormal pain inhibition. However, these results might have been confounded by residual dopaminergic medication.Methods: An established conditioned pain modulation paradigm was used in 17 drug-naïve de novo PD patients and 17 healthy age and gender-matched controls. We tested i) whether conditioned pain modulation responses differed between the patient and control group and ii) whether pain inhibition differed between PD subtypes.Results: PD patients and healthy controls did not differ in their conditioned pain modulation responses. Furthermore, there were no significant differences in CPM responses depending on the PD subtype. However, at a descriptive level, tremor-dominant patients showed a tendency for better descending pain inhibition compared to akinetic-rigid and mixed type patients.Conclusions: In this first study investigating conditioned pain modulation in de novo PD patients, we found no additional impairment in descending pain modulation besides the known age-related decline. Our findings indicate that mechanisms other than an impaired descending inhibition contribute to high pain prevalence rates in PD and suggest that mechanisms underlying pain may differ between PD subtypes.

U2 - 10.1186/s42466-019-0029-x

DO - 10.1186/s42466-019-0029-x

M3 - SCORING: Journal article

C2 - 33324893

VL - 1

SP - 27

JO - Neurol Res Pract

JF - Neurol Res Pract

SN - 2524-3489

ER -